Galenika: Production increase and portfolio expansion
03/03/2022 • Customer news
Galenika company, which is a part of the Brazilian NC Group, in 2021 has achieved a significant portfolio expansion, growth in Serbia and in the regional markets, as well as further modernization of business. In the Serbian market, Galenika recorded growth in sales of 13% compared to 2020, and it has grown 25% faster than the market itself, which confirmed its stable 2nd position on the Serbian pharmaceutical market. In the region (Bosnia and Herzegovina, Montenegro and North Macedonia), the sales increase mounts to 33 percents. In both Serbia and the region there has been 31 products registered in 2021, while 29 have been launched already. Also, in 2021, Galenika recorded a production growth of 9% compared to the previous year.
In addition to the region, Galenika operates successfully in 13 international markets in Europe, Middle East and Africa, where it increased exports by 14%, while 19 products were successfully registered on the EU market. Galenika's Institute for Research and Development, in strategic partnership with its sister company in Brazil, EMS, is working on technology transfer of five products from the latest generation of generic drugs. Technology transfers for 2 products have been successfully completed, and the remaining 3 are expected to be completed by the end of April this year.
„Galenika takes a stable market position, which is due to the uncompromising commitment to quality and expansion of the product portfolio in accordance with modern consumers’ needs. Our key drivers of business value include investment, digitization and modernization, as well as providing support to the community in which we operate. Last year was also marked by the internationalization of business with significant growth in the region and in international markets. International business is an area that we will continue to develop in 2022“, said Ricardo Vian Marques, the CEO of Galenika.
For more information, visit the link.